New drug cocktail shows promise for Hard-to-Treat lymphoma
NCT ID NCT05025800
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This study is testing a combination of three drugs—ALX148, rituximab, and lenalidomide—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see if the combination can shrink or control the cancer. About 47 participants will take part at a single center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALX148 (an immunotherapy drug), rituximab (a targeted antibody), and lenalidomide (a chemotherapy drug)
What this could lead to
If it works, this combination could offer a new treatment option for people with certain types of B-cell non-Hodgkin lymphoma that haven't responded to other therapies.
What could go wrong
This is an early-phase trial with only 47 participants, so results may not apply to everyone. The drugs can cause side effects, and the combination may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.